[Fixed points and open questions in the treatment of superficial bladder carcinoma].
Altieri
Vincenzo
V
Cattedra di Urologia, Area Funzionale di Urologia Oncologica e Chirurgia Endourologica, Universita Federico II di Napoli. altieri@unina.it
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use; D002291:Carcinoma, Papillary / Q000628:therapy*; D006801:Humans; D016685:Mitomycin / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D001500:BCG Vaccine; D016685:Mitomycin